Please assess the completion status of the following clinical trial:

Trial Title: Immunopharmacological Effects of Rituximab in Atopic Dermatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must give written informed consent.~* Must be at least 18 years of age.~* Must have been diagnosed with atopic dermatitis fulfilling the diagnostic criteria of Hanfin and Rajka and having active inflammation.~* Must have a severity score of 6-9 according to Langeland and Rajka.~* Must have a PGA of severe or very severe and a pruritus score of moderate or severe at baseline.~Exclusion Criteria:~* Patients with other skin diseases that might interfere with the evaluation of AD.~* Patients with severe diseases of other organ systems (e.g. cardiovascular, liver, kidney, psychiatric, neurologic) that might put the patient on risk during the study or might interfere with the evaluations (in the opinion of the investigator).~* Patient older than 65 years.~* Systemic treatment for atopic dermatitis (e. g. corticosteroids, cyclosporine, mycophenolat-mofetil, interferon-gamma, UVB, UVA, PUVA) or systemic treatment with immunosuppressive/immunomodulating substances (e.g. azathioprin, methotrexate, biologics or hyposensitization -therapy) within 28 days prior to baseline.~* Local treatment for atopic dermatitis with pimecrolimus/tacrolimus, steroids \> class III, instable use of steroids class \<III, emollients or local antiseptics/antibiotics within 14 days prior to day 1.~* Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within 3 months prior to the first dose of Rituximab.~* History of recurrent clinically significant infection.~* Congenital or acquired immunodeficiency syndrome.~* History of or a new diagnosis or treatment of an invasive malignancy within 5 years of enrollment. Patients with a history of treated squamous cell and/or basal cell carcinomas limited to the skin are not excluded.~* For female patients, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as defined by the investigator, during the study. The rhythm method is not to be used as the sole method of contraception. Female patients considering becoming pregnant while in the study are excluded.~* Female patients who are currently pregnant or breast-feeding.~* Current enrollment in any other investigational drug study.~* Previous participation in this study or previous studies with Rituximab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients with atopic dermatitis.

Based on this trial design, predict the completion outcome and termination type (if applicable).